Literature DB >> 33761116

Margetuximab: First Approval.

Anthony Markham1.   

Abstract

The second-generation anti-human epidermal growth factor receptor2 protein (HER2) monoclonal antibody margetuximab (MARGENZA™, margetuximab-cmkb) is being developed for the treatment of HER2-positive breast cancer, gastric cancer and gastro-oesophageal junction cancer. The antibody has been engineered for increased binding to activating Fcγ receptor IIIA (CD16A) and decreased binding to inhibitory Fcγ receptor IIB (CD32B) relative to trastuzumab with the aim of improving response rates. Based on the results of the phase III SOPHIA trial margetuximab has been approved in the USA for use in combination with chemotherapy as treatment of previously-treated metastatic HER2-positive breast cancer. This article summarizes the milestones in the development of margetuximab leading to this first approval.

Entities:  

Year:  2021        PMID： 33761116     DOI： 10.1007/s40265-021-01485-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  2 in total

1.  MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.

Authors:  Daniel Vt Catenacci; Minori Rosales; Hyun Cheol Chung; Harry H Yoon; Lin Shen; Markus Moehler; Yoon-Koo Kang
Journal:  Future Oncol       Date:  2020-12-02       Impact factor: 3.404

2.  Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

Authors:  Otto Metzger Filho; Daniel G Stover; Sarah Asad; Peter J Ansell; Mark Watson; Sibylle Loibl; Charles E Geyer; Junu Bae; Katharine Collier; Mathew Cherian; Joyce O'Shaughnessy; Michael Untch; Hope S Rugo; Jens B Huober; Mehra Golshan; William M Sikov; Gunter von Minckwitz; Priya Rastogi; David Maag; Norman Wolmark; Carsten Denkert; W Fraser Symmans
Journal:  JAMA Oncol       Date:  2021-04-01       Impact factor: 31.777
  2 in total
  2 in total

Review 1.  Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies.

Authors:  Juan J Mata-Molanes; Joseba Rebollo-Liceaga; Elena Mª Martínez-Navarro; Ramón González Manzano; Antonio Brugarolas; Manel Juan; Manuel Sureda
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

2.  Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Jindong Xie; Yutian Zou; Ting Gao; Liming Xie; Duxun Tan; Xiaoming Xie
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.